Results 231 to 240 of about 171,882 (296)

Patient Perspective: How Patient Values Set a Historic Benchmark for the ESC/EACTS Guidelines 2025 for the Management of Valvular Heart Disease. [PDF]

Eur Cardiol
Mores B.
europepmc   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Probing the Relationship Between Perioperative Complications in Patients With Valvular Heart Disease: Network Analysis Based on Bayesian Network. [PDF]

JMIR Form Res
Lu W, Zhu K, Gao Z, Li Y, Tang H, Sun C, Hou J.   +6 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

A path forward for the implementation of shared decision-making in valvular heart disease: global joint recommendations from clinicians, patients and researchers. [PDF]

Health Res Policy Syst
Lauck SB, Gulati M, Lewis KB, Straiton N, Takkenberg JJM, Nia PS, McGonigle S, Padilla K, Ross E, Eltchaninoff H, Prendergast B.   +10 more
europepmc   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. [PDF]

Heart
Pang L, Xia Y, Tang M, Ma M, Ran H, Zhao Z, Wang T, Yang J, Li J, Zhou Y, Duo L, Luo Z, Zhu D.   +12 more
europepmc   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source